Literature DB >> 11326647

The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.

G Schulze1.   

Abstract

The present study is designed to evaluate the use of the tumor marker Tumor M2-PK in the discrimination between gastrointestinal (Gl) cancer patients and patients with non malignant gastrointestinal diseases. The concentration of Tumor M2-PK was analyzed in EDTA-plasma of 413 Gl cancer-patients and 141 patients with non-malignant diseases. The test resulted in a highly significant discrimination (p < 0.001) of tumor patients and controls. The diagnostic specificity was 89%. A diagnostic sensitivity between 48% and 73%, depending on the different tumor entities (colorectal cancer, gastric cancer, oesophageal cancer and pancreatic cancer), was observed. These sensitivities were generally higher when compared with those of the established tumor markers CEA, CA 19-9 and CA 72-4, with the exception of CA 19-9 in pancreatic cancer. A combination of Tumor M2-PK with the appropriate first choice-marker (e.g. CEA + Tumor M2-PK for colorectal cancer) resulted in a remarkable increase in the sensitivities.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11326647

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Proteomic identification of differentially-expressed proteins in esophageal cancer in three ethnic groups in Xinjiang.

Authors:  Zan Liu; Jun-Guo Feng; Aerziguli Tuersun; Tao Liu; Hui Liu; Qing Liu; Shu-Tao Zheng; Cong-Gai Huang; Guo-Dong Lv; Ilyar Sheyhidin; Xiao-Mei Lu
Journal:  Mol Biol Rep       Date:  2010-12-02       Impact factor: 2.316

2.  Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening.

Authors:  Wen Meng; Hong-Hong Zhu; Ze-Feng Xu; Shan-Rong Cai; Qi Dong; Qiang-Rong Pan; Shu Zheng; Su-Zhan Zhang
Journal:  World J Gastrointest Oncol       Date:  2012-06-15

3.  The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.

Authors:  K Koss; R F Harrison; J Gregory; S J Darnton; M R Anderson; J A Z Jankowski
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

4.  Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients.

Authors:  Daniel Fatela-Cantillo; Antonio Fernandez-Suarez; Miguel Alonso Marin Moreno; Juan Jesus Puente Gutierrez; Jose Miguel Diaz Iglesias
Journal:  Tumour Biol       Date:  2012-01-10

5.  Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.

Authors:  Maurizio Ventrucci; Antonio Cipolla; Chiara Racchini; Riccardo Casadei; Patrizia Simoni; Lucio Gullo
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

6.  Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia.

Authors:  Mark M Aloysius; Abed M Zaitoun; Timothy E Bates; Abdulkader Albasri; Mohammad Ilyas; Brian J Rowlands; Dileep N Lobo
Journal:  BMC Cancer       Date:  2009-09-15       Impact factor: 4.430

7.  Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer.

Authors:  Jae Yun Lim; Sun Och Yoon; So Young Seol; Soon Won Hong; Jong Won Kim; Seung Ho Choi; Jae Yong Cho
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

Review 8.  Glucose metabolic phenotype of pancreatic cancer.

Authors:  Anthony K C Chan; Jason I E Bruce; Ajith K Siriwardena
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

9.  Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls.

Authors:  Bo Zhang; Jian-Ying Chen; Dao-Da Chen; Guo-Bin Wang; Ping Shen
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

10.  Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma.

Authors:  Xiao-Li Du; Hai Hu; De-Chen Lin; Shu-Hua Xia; Xiao-Ming Shen; Yu Zhang; Man-Li Luo; Yan-Bin Feng; Yan Cai; Xin Xu; Ya-Ling Han; Qi-Min Zhan; Ming-Rong Wang
Journal:  J Mol Med (Berl)       Date:  2007-02-22       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.